Q1 Earnings Estimate for DWTX Issued By Zacks Research

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Equities researchers at Zacks Research issued their Q1 2026 EPS estimates for Dogwood Therapeutics in a research note issued to investors on Monday, March 23rd. Zacks Research analyst D. Bautz forecasts that the company will post earnings per share of ($0.13) for the quarter. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share. Zacks Research also issued estimates for Dogwood Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.47) EPS and FY2028 earnings at ($0.40) EPS.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings results on Wednesday, March 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.96.

Several other analysts have also issued reports on DWTX. Wall Street Zen lowered Dogwood Therapeutics to a “strong sell” rating in a report on Saturday, December 13th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Dogwood Therapeutics in a research note on Friday, February 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Price Performance

Shares of NASDAQ DWTX opened at $2.31 on Thursday. The stock has a market capitalization of $77.16 million, a PE ratio of -0.12 and a beta of 1.90. The business has a fifty day moving average price of $2.94 and a two-hundred day moving average price of $4.61. Dogwood Therapeutics has a fifty-two week low of $2.26 and a fifty-two week high of $9.50.

Institutional Investors Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP bought a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics as of its most recent filing with the SEC. Institutional investors own 9.05% of the company’s stock.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.